Trinean Announces Closing of a 3.5 Million Euro Funding Round
[ Back ]   [ More News ]   [ Home ]
Trinean Announces Closing of a 3.5 Million Euro Funding Round

GENTBRUGGE, BELGIUM -- OCTOBER 20, 2008 -- Trinean NV, an innovative player in the sector of molecular instrumentation, today announced the closure of a 3,5 million Euro round of financing. The round was co-lead by new investor Vesalius Biocapital and existing investor Capital-E. Trinean ( www.trinean.com) is a spin-off of the University of Ghent (Intec) and the Belgium nanoelectronics research center IMEC.

The company develops and markets the first nanoliter spectrophotometer with corresponding micro fluidic consumables allowing full spectrum UV/VIS spectroscopic measurements in droplets of liquids between 0,5 and 2,5 µL in a microplate format in a very fast and automated way.

The initial target application is the determination of DNA/RNA concentrations in small sample volumes. This is of great importance to the biotech industry where today valuable DNA/RNA material has to be sacrificed in order to measure these concentrations, and where test procedures are time consuming.

Next to DNA/RNA quantification, other applications will also be targeted such as ADME testing, protein concentration measurements, enzymology, nephelometry and clinical diagnostics.

The investment round will allow Trinean to start production, bring its products to the market and develop new applications.

The company is run by a senior management team consisting of Jan Boon (COO), (ex-Elscolab, Thermo Life Sciences, Flow Laboratories , Pharmacia Diagnostics….) and Prof. Marc Zabeau (CEO) (ex- Plant Genetic Systems, Helix, KeyeGene, Genscope, Methexis…).

About Trinean

Trinean is a developer and producer of nanoliter spectrophotometers and consumables for the scientific market. The use of a unique polychromatic spectroscopy system combined with microfluidic chips in microplate format, provides the world-wide scientists a gain of time, accuracy and costly samples and reagents, which is of high importance to the biotech applications. More information can be obtained at www.trinean.com.

About Vesalius Biocapital

See www.vesaliusbiocapital.com

About Capital-E

Capital-E is an early stage venture fund focused exclusively on micro- and nano-electronics related ventures in Europe. We help initiate and grow businesses with venture capital, sound advice and access to a broad industry network and research ecosystem. Through its entrenched relationship with IMEC, a world-leading independent research centre in nano-electronics, the fund and its ventures can directly rely on the support of over 1600 specialised scientists and engineers, as well as leverage on IMEC's 1000+ worldwide industrial partners to speed-up the process of market entry. The fund is managed by an independent team with a balanced mix of entrepreneurial, industrial and VC experience. More information can be obtained at www.capital-e.com.



Contacts:

Jan Boon
COO Dulle Grietlaan
17/3 B-9050 Gentbrugge
Tel.: 09 272 7535
E-mail: Email Contact

Katrien Marent
IMEC
Director, External Communications
Tel.: +32 16 28 18 80
E-mail: Email Contact

Barbara Kalkis
Maestro Marketing & PR
Tel.: +1 408 996 9975, M: 1 408 529 4210
E-mail: Email Contact